Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atrasentan · 1 trial · 2 indications
Percentage of Subjects with a Sperm Concentration \< 15 million per mL by Treatment Week 26. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.
| Arm | Type | Description |
|---|---|---|
| Atrasentan | EXPERIMENTAL | Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks |
| Name | Type | Description |
|---|---|---|
| Atrasentan | DRUG | Atrasentan |
Inclusion Criteria: * Males 30 to 75 years of age * Type 1 or 2 diabetes and receiving treatment with at least one anti-hyperglycemic medication and angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) (renin-angiotensin system \[RAS\] inhibitor) * Estimated Glomerula...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| DexCom, Inc. | DXCM | 1 | PHASE3 | Sotagliflozin |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | - | Renal Autologous Cell Therapy |
Atrasentan is an investigational small molecule being developed for chronic kidney disease and nephropathy, specifically diabetic nephropathy. It is studied for its effect on reducing albuminuria in patients with type 2 diabetic nephropathy who are treated with renin-angiotensin system inhibitors.
Atrasentan is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The drug is currently in Phase 2 clinical development for chronic kidney disease and nephropathy.
Atrasentan is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Four Phase 2 clinical trials have been completed, with no active trials currently ongoing.
Atrasentan has completed four Phase 2 clinical trials. These include NCT00920764, NCT01356849, NCT01399580, and NCT01424319. All trials focused on chronic kidney disease and diabetic nephropathy, with a total enrollment of 347 participants across the United States, Canada, Puerto Rico, Taiwan, and Japan.
Atrasentan is also known by the code name ABT-627. It is an investigational small molecule being studied for chronic kidney disease and nephropathy. The drug is in Phase 2 development and has completed four clinical trials.